This content is for informational purposes only and is not medical advice. Treatment eligibility, medication choice, and dosing are determined by a licensed healthcare provider based on your individual medical history and clinical needs. Do not start, stop, switch, or change the dose of a prescription medication without your prescribing clinician.
In This Guide
- How semaglutide and tirzepatide work
- Key differences at a glance
- What the head-to-head weight-loss evidence shows
- Safety and tolerability considerations
- How to choose with a clinician
- FDA-approved and compounded products are not interchangeable
- Questions to ask before deciding
- Frequently asked questions
- The bottom line
Key Takeaways
Q: Are semaglutide and tirzepatide the same medication? A: No. Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. They are different prescription drugs with separate FDA labeling.
Q: Which produced more average weight loss in a direct trial? A: In the 72-week SURMOUNT-5 trial of adults with obesity but without diabetes, tirzepatide produced a larger average weight reduction than semaglutide at the maximum tolerated doses studied. That group result does not predict an individual person’s outcome.
Q: Does that make tirzepatide the best choice for everyone? A: No. Medical history, labeled indication, contraindications, side effects, other medicines, pregnancy plans, access, cost, and prior response can all change the decision.
Q: Can trial results for Wegovy or Zepbound be applied to compounded products? A: No. Compounded drugs are not FDA-approved, and results from an approved product should not be transferred to a compounded preparation as though the products were equivalent.
Q: Should you switch if progress is slower than expected? A: Not on your own. A clinician should first review tolerability, time on treatment, the dose actually reached, adherence, nutrition, activity, other health conditions, and whether a switch is appropriate.
How semaglutide and tirzepatide work
Semaglutide and tirzepatide are incretin-based medications. They affect signaling involved in appetite, food intake, and glucose regulation, but they do not act in exactly the same way.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. For chronic weight management, the relevant FDA-approved branded product is Wegovy. Semaglutide is also sold under other brand names for different indications, so the product, indication, and dose matter when reading evidence.
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. For chronic weight management, the relevant FDA-approved branded product is Zepbound. Tirzepatide is also marketed under a different brand for type 2 diabetes.
Both weight-management products are used with a reduced-calorie diet and increased physical activity under their current U.S. labels. Both are prescription treatments, and neither replaces clinical follow-up, nutrition, movement, sleep, or other parts of long-term obesity care.
Key differences at a glance
| Comparison point | Semaglutide for weight management | Tirzepatide for weight management |
|---|---|---|
| FDA-approved brand discussed here | Wegovy | Zepbound |
| Receptor activity | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Administration | Once-weekly subcutaneous injection under the approved label | Once-weekly subcutaneous injection under the approved label |
| Direct obesity trial | Comparator in SURMOUNT-5 at maximum tolerated 1.7 mg or 2.4 mg | Comparator in SURMOUNT-5 at maximum tolerated 10 mg or 15 mg |
| Common practical concerns | Gastrointestinal effects, gradual dose escalation, coverage and availability | Gastrointestinal effects, gradual dose escalation, coverage and availability |
| Decision standard | Individual clinical fit, not a single headline result | |
Current details should always be checked in the official Wegovy prescribing information and Zepbound prescribing information. Labels can change as indications and safety information evolve.
What the head-to-head weight-loss evidence shows
The most useful direct comparison is the SURMOUNT-5 trial published in the New England Journal of Medicine. It enrolled 751 adults with obesity but without type 2 diabetes and compared the maximum tolerated dose of weekly tirzepatide with the maximum tolerated dose of weekly semaglutide for 72 weeks.
Average weight change was 20.2% with tirzepatide and 13.7% with semaglutide in the trial’s primary analysis. Tirzepatide also produced a larger average reduction in waist circumference. Gastrointestinal events were the most common adverse events in both groups and were generally mild to moderate, occurring mainly during dose escalation.
Those numbers need context. The study was open-label, used specific FDA-approved products and dose ranges, enrolled adults without diabetes, and was funded by Eli Lilly, the manufacturer of tirzepatide. It compared group averages under a research protocol, not guaranteed results in routine care. It does not establish that every person will lose more weight with tirzepatide, and it does not compare compounded formulations.
Why separate trials are harder to compare
It is tempting to compare percentages from unrelated semaglutide and tirzepatide studies. That can mislead because trials may differ in population, diabetes status, duration, dose, handling of missing data, lifestyle support, and the way outcomes are calculated. A direct randomized comparison is more informative, but it still cannot replace an individualized clinical decision.
Safety and tolerability considerations
Both medications commonly cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, abdominal discomfort, or indigestion. Symptoms often become more noticeable during dose escalation, which is one reason clinicians increase treatment gradually according to the applicable label and the patient’s response.
Both labels carry a boxed warning about thyroid C-cell tumors observed in rodents and contraindicate use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The labels also address serious risks and precautions including pancreatitis, gallbladder disease, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity, and concerns around procedures requiring anesthesia or deep sedation.
The complete risk profile is longer and product-specific. A prescriber should review your medical history, symptoms, other medicines, pregnancy or pregnancy plans, and prior reactions. If you are already in treatment, our guide to managing GLP-1 side effects explains general self-care and when to contact a clinician. Severe or persistent symptoms require timely medical attention.
How to choose with a clinician
The better medication is the one that is clinically appropriate, tolerable, accessible, and sustainable for the individual patient. A clinician may consider several factors rather than choosing on average weight loss alone.
- Indication and health history: The clinician must confirm that the proposed product fits the patient’s condition and review contraindications and precautions.
- Diabetes and cardiovascular context: Product indications and supporting evidence differ. The exact reason for treatment matters.
- Tolerability: A medication that produces unacceptable side effects may not be sustainable, even if its trial average is higher.
- Other medicines: Incretin-based treatments can affect glucose management and slow gastric emptying, which may matter with other drugs.
- Coverage and total cost: Insurance rules, prior authorization, cash price, pharmacy access, and program fees vary. Coverage is never guaranteed.
- Goals beyond the scale: Clinical priorities may include cardiometabolic risk, sleep apnea, mobility, preservation of lean mass, and long-term maintenance.
A thoughtful review also looks at nutrition and function. Our article on preserving muscle during GLP-1 weight loss explains why adequate nutrition, resistance exercise, and clinical monitoring deserve attention alongside the scale.
What if the first medication does not work well enough?
A slower-than-hoped response is not, by itself, a reason to switch. A prescriber may first review how long the person has been treated, whether the tolerated maintenance dose was reached, side effects, adherence, eating patterns, activity, sleep, other medications, and conditions that can affect weight. Switching requires a clinical plan; do not overlap products or improvise timing.
For general context on how clinicians approach gradual changes, see managing GLP-1 dose adjustment safely.
FDA-approved and compounded products are not interchangeable
The evidence above applies to the FDA-approved products studied. Compounded semaglutide and compounded tirzepatide are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed, and a compounded preparation should not be called a generic version of Wegovy or Zepbound.
FDA’s current page on unapproved GLP-1 drugs used for weight loss describes concerns including fraudulent labeling, dosing errors, use of semaglutide salt forms, and adverse-event reports. FDA advises that compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug and that prescriptions should be filled at a state-licensed pharmacy.
If a clinician proposes a compounded product, ask why an FDA-approved option does not meet the clinical need, which pharmacy will make it, what exact ingredient and concentration are prescribed, and how instructions will be communicated. Never convert milligrams to syringe units or change a compounded dose without direct instructions from the prescriber and dispensing pharmacy.
Questions to ask before deciding
- Which exact product and indication are you recommending, and why does it fit my medical history?
- What benefits are realistic for me, and what would count as an adequate response?
- Which side effects should prompt a routine message, an urgent call, or emergency care?
- How will this treatment interact with my other medicines or planned procedures?
- How will you monitor nutrition, hydration, muscle function, and metabolic health?
- Is the proposed medication FDA-approved or compounded?
- What are the full costs, including medication, visits, labs, supplies, and shipping?
- What is the plan if I cannot tolerate the medication or lose coverage?
For more background on finding legitimate medication access, see our guides to finding semaglutide online safely and finding a safe online tirzepatide provider.
Frequently asked questions
In the 72-week SURMOUNT-5 trial, adults with obesity but without diabetes lost more weight on average with tirzepatide than with semaglutide at the maximum tolerated doses studied. That does not mean tirzepatide is the right or more effective choice for every individual.
Do not combine or overlap these prescription medications unless a qualified prescriber gives explicit instructions. Their approved labels do not support using them together for weight management, and doing so may increase risk.
They share many common gastrointestinal effects, but they are different drugs with separate labels and individual responses vary. Review the full prescribing information and your medical history with a clinician.
A switch may be appropriate for some patients, but timing and dose selection require a prescriber’s plan. Do not stop, overlap, or restart either medication on your own.
No. Compounded drugs are not FDA-approved, and FDA does not review them before marketing for safety, effectiveness, or quality. Clinical-trial results for Wegovy and Zepbound should not be assumed to apply to compounded preparations.
The bottom line
Tirzepatide produced more average weight loss than semaglutide in a direct 72-week obesity trial, but medication choice is not a one-number decision. The right plan depends on the exact product and indication, medical history, risks, tolerability, access, cost, and the follow-up available to support treatment.
This article provides general education about FDA-approved semaglutide and tirzepatide products and does not recommend a medication or dose. A licensed clinician should review your history and the current prescribing information before making or changing a treatment plan. Seek prompt medical attention for severe or concerning symptoms.
